Literature DB >> 21466490

Mucosal healing in ulcerative colitis: where do we stand?

Gionata Fiorino1, Monica Cesarini, Amedeo Indriolo, Alberto Malesci.   

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any short-term medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited. This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.

Entities:  

Mesh:

Year:  2011        PMID: 21466490     DOI: 10.2174/138945011796818216

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  6 in total

1.  Mucosal healing with infliximab: results from the active ulcerative colitis trials.

Authors:  William J Sandborn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

Review 2.  The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease.

Authors:  Michel Neunlist; Laurianne Van Landeghem; Maxime M Mahé; Pascal Derkinderen; Stanislas Bruley des Varannes; Malvyne Rolli-Derkinderen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-11-20       Impact factor: 46.802

3.  Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.

Authors:  Jung-Wook Kim; Hyo Jong Kim; Chang Kyun Lee; Jae-Jun Shim; Jae Young Jang; Suk Ho Dong; Byung-Ho Kim; Young Woon Chang; Sung-Gil Chi
Journal:  Dig Dis Sci       Date:  2014-07-23       Impact factor: 3.199

4.  A novel endoscopic imaging system for quantitative evaluation of colonic mucosal inflammation in patients with quiescent ulcerative colitis.

Authors:  Yusuke Honzawa; Minoru Matsuura; Hirokazu Higuchi; Takaki Sakurai; Hiroshi Seno; Hiroshi Nakase
Journal:  Endosc Int Open       Date:  2020-01-08

5.  Simplified Histologic Mucosal Healing Scheme (SHMHS) for inflammatory bowel disease: a nationwide multicenter study of performance and applicability.

Authors:  A Caputo; P Parente; M Cadei; M Fassan; A Rispo; G Leoncini; G Bassotti; R Del Sordo; C Metelli; M Daperno; A Armuzzi; V Villanacci
Journal:  Tech Coloproctol       Date:  2022-06-01       Impact factor: 3.699

6.  Significance of Linked Color Imaging for Predicting the Risk of Clinical Relapse in Ulcerative Colitis.

Authors:  Shuji Kanmura; Akihito Tanaka; Kazuki Yutsudou; Kosuke Kuwazuru; Fukiko Komaki; Yuga Komaki; Hiromichi Iwaya; Shiho Arima; Fumisato Sasaki; Shiroh Tanoue; Shinichi Hashimoto; Akio Ido
Journal:  Gastroenterol Res Pract       Date:  2020-03-06       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.